Recent studies demonstrate exciting potential of intranasal NPY or selective agonists to attenuate the development of immune-challenge and stress-elicited behavioral changes, as well as neurodegenerative diseases like Huntington’s disease [10,11,12,13]. The gene discussed is NPY; the disease is juvenile Huntington disease.